CardioGenics (CGNH.OB) Inks “Key Milestone” Commercialization Agreement with Merck-Chimie
CardioGenics Holdings Inc. develops ultra-sensitive analyzers and other products for the Point-of-Care IVD testing market. The company today announced an agreement with Merck-Chimie S.A.S. to commercialize CardioGenics’ proprietary paramagnetic beads to Merck-Chimie’s customers. Bead shipments will commence in mid-September of this year. Merck-Chimie is a leading supplier of paramagnetic diagnostic beads, which are integral to every immunoassay analyzer. The bead’s role as a key analyzer component to reflect a broader market valued at roughly $1 billion. CardioGenics' technology improves the signaling properties of the beads, which increases the sensitivity of immunoassay analyzers up to seven times and allows for enhanced…